rafal.smigrodzki at gmail.com
Mon Sep 5 11:25:44 UTC 2016
On Mon, Sep 5, 2016 at 2:04 AM, Keith Henson <hkeithhenson at gmail.com> wrote:
> In its highest dose, the drug was recently shown to annihilate amyloid
> plaques in the brains of a subset of the study’s 165 participants.
> It could cost up to $2.5 billion dollars to test it widely, but the
> investment might be worth the price tag: if it works, aducanumab could
> treat people for Alzheimer’s before they even show symptoms.
> ### There was a 41% frequency of ARIA (brain swelling) at the highest
dose, which was dose-dependent and lead to discontinuation of treatment in
44% affected patients. There were also many cases of CNS siderosis. So,
another amyloid-buster antibody that causes brain swelling like all the
others before it, with dose-dependent loss of study participants that can
explain the trends towards efficacy.
I give you 3:1 odds against it working in phase III.
-------------- next part --------------
An HTML attachment was scrubbed...
More information about the extropy-chat